Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$283.04
neg -8.10
-2.80%
Today's Range: 280.50 - 288.97 | BIIB Avg Daily Volume: 1,542,600
Last Update: 12/07/16 - 1:39 PM EST
Volume: 1,186,444
YTD Performance: -4.96%
Open: $285.86
Previous Close: $291.16
52 Week Range: $223.02 - $338.51
Oustanding Shares: 217,574,479
Market Cap: 63,144,465,295
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 9 8 8
Moderate Buy 1 1 1 1
Hold 4 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.78 1.83 1.83
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 19.72
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
19.72 17.80 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.28% 2.36% 0.09%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.90 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.60 0.38
Earnings for BIIB:
EBITDA 4.28B
Revenue 9.42B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $5.00 $4.97 $20.22 $20.80
Number of Analysts 18 12 17 18
High Estimate $5.50 $5.39 $20.69 $23.31
Low Estimate $4.68 $4.63 $19.86 $19.17
Prior Year $4.50 $4.79 $17.01 $20.22
Growth Rate (Year over Year) 11.06% 3.67% 18.85% 2.87%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The worst appears to be over for this sector; we could see big growth ahead.
Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.
The bullish side dominates, with consumer cyclicals and energy names most prevalent.
With the election resolved, biotech could be ripe for consolidation.
Bullish
Nov 07, 2016 | 7:22 AM EST
BIIB was upgraded from Neutral to Overweight, Piper Jaffray said. $335 price target. Valuation is reasonable, given opportunities in Al...
Check out this biotech ETF, and Biogen, for plays on any recovery.
Bearish
Sep 06, 2016 | 7:02 AM EDT
BIIB was downgraded to Hold, Jefferies said. Valuation call, based on a $323 price target.
The leadership is quite stark.
Las Vegas Sands (LVS) continues to show strength after Bank of America/Merrill Lynch put out an optimistic note this morning about Macau gambling. Energy is weak in early trading. Oil has drifted back down to around $47 a barrel following its recent roughly 20% rally.

Bret Jensen Reporting for Duty Real Money Pro($)

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week.

Columnist Conversations

This stock is having a strong day with great volume, good flow lately (Feb 140 strikes) and a potential breako...
This chart is starting to break out nicely, outside day here. BOUGHT DG JAN 77.5 CALL AT 1.85
Market mixed with NASDAQ down a good amount.  Biotech down 3% as it is the "Trump Special" of the day. &n...
We bought some calls yesterday and rolled up.  This chart is fantastic, I'll have that out for everyone o...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.